<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Chapter 1 Drug Development Perspective - Illiterate&#39;s blog</title>
    <meta property="og:title" content="Chapter 1 Drug Development Perspective - Illiterate&#39;s blog">
    
    <meta name="twitter:card" content="summary">

    
      
    

    
      
      <meta property="description" content="Reducing attrition biomedical approaches
[&amp;hellip;] leverage pre-existing information including bioinformatics approaches
[&amp;hellip;] integrating non-clinical information to predict clinical properties &amp;hellip;">
      <meta property="og:description" content="Reducing attrition biomedical approaches
[&amp;hellip;] leverage pre-existing information including bioinformatics approaches
[&amp;hellip;] integrating non-clinical information to predict clinical properties &amp;hellip;">
      
    

    
    
    <meta name="twitter:image" content="https://i.loli.net/2021/03/05/zFRK9lYedsAHbh8.png">
    
    

    

    
    




    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    
  </head>

  
  <body class="posts">
    <header class="masthead">
      <h1><a href="/">Illiterate&#39;s blog</a></h1>

<p class="tagline">Personal website of illiterate</p>

      <nav class="menu">
  <input id="menu-check" type="checkbox" hidden/>
  <label id="menu-label" for="menu-check" class="unselectable" hidden>
    <span class="icon close-icon">✕</span>
    <span class="icon open-icon">☰</span>
    <span class="text">Menu</span>
  </label>
  <ul>
  
  
  <li><a href="/">首页</a></li>
  
  <li><a href="/posts">日志</a></li>
  
  <li><a href="/categories/">分类</a></li>
  
  <li><a href="/tags/">标签</a></li>
  
  <li><a href="about/">关于</a></li>
  
  
  </ul>
</nav>

    </header>

    <article class="main">
      <header class="title">
      
<h1>Chapter 1 Drug Development Perspective</h1>

<h3>
  2021-03-05</h3>
<hr>


      </header>



<h1 id="critical-steps-enabling-early-development">Critical steps enabling early development</h1>
<p>Reducing attrition biomedical approaches</p>
<ul>
<li>
<p>leverage pre-existing information including bioinformatics approaches</p>
</li>
<li>
<p>integrating non-clinical information to predict clinical properties of NME</p>
</li>
<li>
<p>optimize the operational costs to gain timely information in early trials</p>
</li>
</ul>
<h2 id="non-clinical-pharmacokinetic-pk-studies">non-clinical pharmacokinetic (PK) studies</h2>
<ul>
<li>
<p>PK profile in animals is first used to optimize subsequent formulation</p>
</li>
<li>
<p>support non-clinical pharmacology and toxicology studies</p>
</li>
</ul>
<h2 id="pharmacokineticpharmacodynamic-pkpd-models">pharmacokinetic/pharmacodynamic (PK/PD) models</h2>
<p>to design</p>
<ul>
<li>
<p>non-clinical toxicology studies in animals</p>
</li>
<li>
<p>determine of drug requirements for CMC</p>
</li>
<li>
<p>Time points for PK sampling in humans</p>
</li>
<li>
<p>estimate the safe starting dose</p>
</li>
<li>
<p>assess the benefit/risk for a NME</p>
</li>
</ul>
<p><img src="https://i.loli.net/2021/03/05/zFRK9lYedsAHbh8.png" alt="Fig 1.2"></p>
<h2 id="pharmacology-and-toxicology-studies">pharmacology and toxicology studies</h2>
<h2 id="non-clinical-pharmacology-models">Non-clinical Pharmacology Models</h2>
<ul>
<li>
<p>PDX(patient-derived xenografts) <strong>BETTER THAN</strong> CDX(non-clinical cell line derived xenograft)</p>
</li>
<li>
<p>Notice differences of the species-specific immune system</p>
</li>
<li>
<p>human organoids may help</p>
</li>
</ul>
<h3 id="non-clinical-toxicology-studies">Non-clinical Toxicology Studies</h3>
<p>based on ICH S9</p>
<ul>
<li>
<p>most relevant species: generally a rodent and non-rodent species</p>
</li>
<li>
<p>determine the no-observed adverse effect level (NOAEL)</p>
</li>
</ul>
<p>true positive concordance rate between animal and human: 71%</p>
<h2 id="biomarker-development-plans">biomarker development plans</h2>
<p>Success rate: 13% vs. 7%</p>
<h1 id="immuno-oncology">Immuno-oncology</h1>
<ul>
<li>
<p>include therapeutic vaccines and NME targeting immune cells</p>
</li>
<li>
<p>not have an immediate antitumor effect and long treatment times</p>
</li>
<li>
<p>Monitoring immune responses for efficacy and safety</p>
</li>
</ul>
<h1 id="planning-for-fih-study">Planning for FiH study</h1>
<h2 id="considerations">Considerations</h2>
<ul>
<li>
<p>Shoud be designed with sufficient decision points</p>
</li>
<li>
<p>no longer just for safety and PK</p>
</li>
<li>
<p>patient selection is key: based on non-clinical model and incorporate PD markers</p>
</li>
<li>
<p>Reducing attrition</p>
<ul>
<li>
<p>anticipated biologically efficacious dose and dose schedule based on PK/PD models</p>
</li>
<li>
<p>safe starting dose based on non-clinical toxicology studies</p>
</li>
<li>
<p>biomarker plan to identify or enrich for patients to respond</p>
</li>
<li>
<p>reduce operational uncertainties by selecting and collaborating with trial centers</p>
</li>
<li>
<p>well trained staff across all parts of the study</p>
</li>
</ul>
</li>
</ul>
<h2 id="fih-design">FiH design</h2>
<p><img src="https://i.loli.net/2021/03/05/UqGnSctTQOgw869.png" alt="Fig 1.3"></p>
<p>Part A: main objective is to confirm the predicted toxicity, PK and, ideally, the PD profile</p>
<ul>
<li>
<p>confirm the prediction of the biological active dose</p>
</li>
<li>
<p>define the biological effective dose (BED) and receptor occupancy</p>
</li>
</ul>
<p>Part B: expansion cohorts</p>
<p>OR flexible design of early phase studies can accelerate the approval</p>
<p><img src="https://i.loli.net/2021/03/05/du1qw2fiQWvmKUE.png" alt="Fig1.4"></p>
<h1 id="accelerate-approval">Accelerate Approval</h1>
<h2 id="additional-studies">Additional Studies</h2>
<ul>
<li>
<p>initiate stability studies as early as possible</p>
</li>
<li>
<p>clinical pharmacology studies</p>
<ul>
<li>
<p>incorporated in ongoing studies or stand-alone</p>
</li>
<li>
<p>include DDI, food effect, QTc, renal &amp; hepatice insufficiency, BA/BE studies</p>
</li>
<li>
<p>Started when the final or pre-final formulation is developed</p>
</li>
</ul>
</li>
<li>
<p>Pediatric asap</p>
</li>
</ul>
<h2 id="regulatory-implications">Regulatory Implications</h2>
<ul>
<li>
<p>Biomarker-driven clinical development have shortened time to registration and may reduced the trials</p>
</li>
<li>
<p>FDA  “accelerated approval” VS. EMA Prime designation</p>
<pre><code>- patient-reported outcomes in EMA

- companion diagnostic in FDA 
</code></pre>
</li>
</ul>
<p><img src="https://i.loli.net/2021/03/05/M2cD9kiwfTNbvhQ.png" alt="Table 1.1"></p>


  <footer>
  
  



<script src="//cdn.bootcss.com/highlight.js//highlight.min.js"></script>



<script>hljs.configure({languages: []}); hljs.initHighlightingOnLoad();</script>



  
  <hr>
  <div class="copyright">© <a href="/">illiterate</a> 2021 - 2025</div>
  
  </footer>
  </article>
  
  </body>
</html>

